Dry Eyes

Ophthalmology
0
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Seed Therapeutics
Seed TherapeuticsNY - New York
1 program
Contact Lens with alginic acidN/A1 trial
Active Trials
NCT01918410CompletedEst. Dec 2014
Bausch + Lomb
Bausch + LombNJ - Bridgewater
1 program
LotemaxN/A1 trial
Active Trials
NCT01695668Completed75Est. Feb 2015

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Seed TherapeuticsContact Lens with alginic acid
Bausch + LombLotemax

Clinical Trials (2)

Total enrollment: 75 patients across 2 trials

NCT01918410Seed TherapeuticsContact Lens with alginic acid

Effect of Contact Lens With Alginic Acid in Dry Eye Patients

Start: Feb 2014Est. completion: Dec 2014
N/ACompleted

Treatment of Ocular Graft-versus-Host Disease (GVHD) With Topical Loteprednol Etabonate 0.5%

Start: Aug 2011Est. completion: Feb 201575 patients
N/ACompleted

Related Jobs in Ophthalmology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space